Avantor Emphasizes Importance of Collaboration, Leveraging Technological Advancements in India Biopharma Forum Series

April 17, 2024 07:34 AM IST | By NewsVoir
 Avantor Emphasizes Importance of Collaboration, Leveraging Technological Advancements in India Biopharma Forum Series
Image source: NewsVoir

Avantor, Inc., a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, hosted first-of-its-kind series of Biopharma forums across India in Bengaluru, Hyderabad and Pune to emphasize Avantor's commitment to creating customized solutions for customers by identifying and addressing the challenges faced by Biopharma companies in India.

Biopharma experts come together at Avantor Biopharma Forum to discuss challenges of biologics manufacturing and its future evolution

The Indian biopharmaceutical industry is rapidly expanding with increased investments in research and development, robust product pipelines, collaborations, and technological advancements. However, challenges such as constantly evolving regulatory compliances and price and quality control impede global competitiveness. The 2024 Avantor Biopharma Forums focused on critical topics including scale-up, risk mitigation, and cost optimization, which are crucial for addressing these challenges and driving growth in the biopharma industry.

With the goal of facilitating an enriching exchange of ideas for professionals within India's Bioprocessing industry, the forums provided a platform for over 600 participants from some of the prominent biopharma players in India to engage with Avantors products and solutions, fostering knowledge exchange and collaboration within the bioprocessing community.

Biopharma specialists and team from Avantor at the Avantor Biopharma Forums held at Bengaluru, Hyderabad and Pune

The highlight of the forums was industry panel discussions with biopharma experts from leading biotechnology and biopharmaceutical companies across the three cities. These discussions explored topics such as the current state-of-the-art in biologics manufacturing, overcoming critical challenges associated with process failure or yield, and the future evolution of biologics manufacturing and digital advancements across the industry

  • Dr. Ger Brophy, Chairman of Avantor's Scientific Advisory Board, spoke about the Readiness for Changing Biological Molecules and Regulatory Environment(1) and shared his perspective about the ever-evolving regulatory environment in the country.

  • Highlighting the evolution of the industry, Mr. Narayana Rao Rapolu, VP, Biopharma and Applied Products Solutions, said, "The Indian biopharma sector is witnessing a rise with the introduction of high-quality, cost-effective biosimilars into the market. At Avantor, we recognize the significant challenges hindering the growth of biopharma companies. With innovative strategies emphasizing efficiency, quality, and affordability, we aim to generate a positive impact on the biopharma business while earning the trust of our customers."

  • Dr. Nandkumar Deorkar, SVP Research and Development, Avantor, shared his insights about the effective management of Total Cost of Ownership in Bioprocessing. "At Avantor, we work to simplify our customers' scale-up processes thereby eliminating process steps. Avantor's objective is to create long- term, strategic partnerships within the industry by working closely with biomanufacturers to drive and foster cost optimization and improve biologics process efficiencies. We are proud to provide exceptional post-sales support and quality assurance, both are key decisive factors in for driving the success of at biopharma companies," said Dr. Deorkar.

The Avantor Biopharma forums were hugely successful in bringing the industry together for meaningful dialogue and exchange. The participants were appreciative of the knowledge sharing sessions and engaging conversations.

About Avantor

Avantor, a Fortune 500 company, is a leading life science tools company and global provider of mission-critical products and services to customers in the life sciences and advanced technology industries. From discovery to delivery, we work side-by-side with scientists around the world to enable breakthroughs in medicine, healthcare, and technology at scale. Our portfolio is used in virtually every stage of the most important research, development and production activities at more than 300,000 customer locations in 180 countries.

For more information, visit avantorsciences.com and find us on LinkedIn, X(Twitter) and Facebook.

(1) Biopharma forum in Bengaluru.


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Limited, Company No. 12643132 (“Kalkine Media, we or us”) and is available for personal and non-commercial use only. Kalkine Media is an appointed representative of Kalkine Limited, who is authorized and regulated by the FCA (FRN: 579414). The non-personalized advice given by Kalkine Media through its Content does not in any way endorse or recommend individuals, investment products or services suitable for your personal financial situation. You should discuss your portfolios and the risk tolerance level appropriate for your personal financial situation, with a qualified financial planner and/or adviser. No liability is accepted by Kalkine Media or Kalkine Limited and/or any of its employees/officers, for any investment loss, or any other loss or detriment experienced by you for any investment decision, whether consequent to, or in any way related to this Content, the provision of which is a regulated activity. Kalkine Media does not intend to exclude any liability which is not permitted to be excluded under applicable law or regulation. Some of the Content on this website may be sponsored/non-sponsored, as applicable. However, on the date of publication of any such Content, none of the employees and/or associates of Kalkine Media hold positions in any of the stocks covered by Kalkine Media through its Content. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media.
The content published on Kalkine Media also includes feeds sourced from third-party providers. Kalkine does not assert any ownership rights over the content provided by these third-party sources. The inclusion of such feeds on the Website is for informational purposes only. Kalkine does not guarantee the accuracy, completeness, or reliability of the content obtained from third-party feeds. Furthermore, Kalkine Media shall not be held liable for any errors, omissions, or inaccuracies in the content obtained from third-party feeds, nor for any damages or losses arising from the use of such content. Some of the images/music/video that may be used in the Content are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music or video used in the Content unless stated otherwise. The images/music/video that may be used in the Content are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.
This disclaimer is subject to change without notice. Users are advised to review this disclaimer periodically for any updates or modifications.


Sponsored Articles


We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.